← All trials
NCT06138600
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2023
- Primary completion
- Oct 31, 2025
- Completion date
- Jan 31, 2026
- First posted
- Nov 18, 2023
- Last posted
- Nov 30, 2023
- Enrollment
- 200
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of the WitwatersrandLead sponsor
- Bill and Melinda Gates FoundationCollaborator
- University of the WitwatersrandReponsible party - principal investigator
- ViiV HealthcareCollaborator
- University of the WitwatersrandSponsor investigator
- Wits Health Consortium (Pty) LtdOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.